Endolymphatic Hydrops Grade M2 Correlates Most Strongly With Hearing Loss
THURSDAY, June 1, 2023 (HealthDay News) -- M2 grading of intracochlear endolymphatic hydrops shows the strongest correlation with hearing loss with Meniere disease, according to a study published online May 17 in Acta Oto-Laryngologica.
Zhihao Han, from the Capital Medical University in Beijing, and colleagues compared the grading consistency and correlation between different grade methods of intracochlear endolymphatic hydrops and hearing loss. The analysis included 31 patients diagnosed with Meniere disease who underwent gadolinium-enhanced magnetic resonance imaging.
The researchers found that the weighted kappa coefficients for interobserver and intraobserver agreements for grading cochlea endolymphatic hydrops using M1 were good, while they were excellent for M2, M3, and M4. Based on M2 cochlear endolymphatic hydrops degree, there was correlation with the low-to-mid frequencies, high frequencies, full frequencies, and Meniere disease clinical stage. For degrees based on M1, M3, and M4, correlations were only relevant for some of the four factors.
"In this study, we summarized the four currently prevailing methods to assess cochlear endolymphatic hydrops. Furthermore, we compared the interobserver and intraobserver agreements of the different methods," the authors write. "The results showed that M2 performed better than the other three methods. Therefore, we recommend the use of M2 for evaluating cochlear endolymphatic hydrops."
Related Posts
Doctors Transplant Kidneys to Children Without Need for Immune-Suppressing Drugs
THURSDAY, June 16, 2022 (HealthDay News) -- Researchers have figured out a way...
EPA Proposes Limits on Dangerous Chemical Used by Medical Sterilization Plants
WEDNESDAY, April 12, 2023 (HealthDay News) – The Environmental Protection Agency...
1 in 5 American Adults Say They Have Relative Killed by a Gun
TUESDAY, April 11, 2023 (HealthDay News) -- Nearly 20% of the American...
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
THURSDAY, Sept. 7, 2023 (HealthDay News) -- The immunotherapy agent atezolizumab...